When your guts have gone nuts, who do you call? These ASX stocks are fighting gastrointestinal disease
Expanded eligibility criteria for IBS and psychological functioning trials
20 May 2022: Yvette Ogilvie, Markets Reporter Link to The Market Herald
Anatara Lifesciences (ANR) has received ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome (IBS) and psychological functioning trials.
The expansion comes after the company was facing a significant screening failure rate due to the strict eligibility criteria.
The approval will expand eligibility to all IBS subtypes with the exception of the constipation subtype.
This allows for 300 potential participants, who previously weren’t able to be enrolled in the trial due to not having diarrhoea predominant IBS.
The psychological functioning trials will now be able to recruit participants from the mild to moderate range of scores on the Depression Anxiety Stress Scale.